Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.80 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27206277 | 0.89 | DPP4 (1.00) | DPP4DPP7 | |
| SCHEMBL30866218 | 0.89 | DPP4 (1.00) | DPP4DPP7 | |
| SCHEMBL27206278 | 0.89 | DPP4 (1.00) | DPP4DPP7 | |
| SCHEMBL5408217 | 0.89 | DPP4 (1.00) | DPP4DPP7 | |
| SCHEMBL3505724 | 0.79 | DPP4 (0.64) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3505719 | 0.79 | DPP4 (0.64) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL4657207 | 0.76 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3504324 | 0.76 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3507073 | 0.76 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 | |
| SCHEMBL3504330 | 0.76 | DPP4 (0.60) | DPP4DPP7CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236102-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236102-A1 | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885CA1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.